Table 1 Demographic and clinical characteristics of participants at baseline
All (n = 119) | EQ-5D-Y Self response (n = 81) | EQ-5D-Y Proxy response (n = 38) | P value | |
|---|---|---|---|---|
Age, mean (SD) | 9.1 (1.7) | 10.1 (1.1) | 7.0 (0.6) | < .001 |
6–7 | 38 (31.9%) | 0 (0.0%) | 38 (100.0%) | < .001 |
8–11 | 81 (68.1%) | 81 (100.0%) | 0 (0.0%) | |
Sex | ||||
Girls | 48 (40.3%) | 29 (35.8%) | 19 (50.0%) | .14 |
Boys | 71 (59.7%) | 52 (64.2%) | 19 (50.0%) | |
Asthma control | .99 | |||
ACQa, mean (SD) | 0.81 (0.93) | 0.81 (0.88) | 0.81 (1.06) | |
Well controlled (< 0.75) | 68 (58.6%) | 43 (54.4%) | 25 (67.6%) | .37 |
Intermediate (0.75–1.5) | 23 (19.8%) | 18 (22.8%) | 5 (13.5%) | |
Not well controlled (> 1.5) | 25 (21.6%) | 18 (22.8%) | 7 (18.9%) | |
Asthmatic exacerbations (last 6 months) | ||||
Yes | 53 (44.5%) | 27 (33.3%) | 26 (68.4%) | < .001 |
No | 66 (55.5%) | 54 (66.7%) | 12 (31.6%) | |
Number of prescribed SABAb | ||||
0 | 9 (7.8%) | 6 (7.6%) | 3 (8.1%) | .72 |
1 | 103 (88.8%) | 71 (89.9%) | 32 (86.5%) | |
2 | 4 (3.4%) | 2 (2.5%) | 2 (5.4%) | |
Frequency of SABA inhaler use (previous 4 weeks) | ||||
No use | 9 (7.8%) | 6 (7.6%) | 3 (8.1%) | .99 |
Less than once per week | 62 (53.4%) | 43 (54.4%) | 19 (51.4%) | |
Once or twice per week | 29 (25.0%) | 19 (24.1%) | 10 (27.0%) | |
Almost every day/Every day | 16 (13.8%) | 11 (13.9%) | 5 (13.5%) | |
Secondhand smoke exposure | ||||
Not exposed | 81 (83.5%) | 55 (84.6%) | 26 (81.3%) | .92 |
Exposed | 16 (16.5%) | 10 (15.4%) | 6 (18.7%) | |
Missing | 22 | 16 | 6 |